172 material Form 8-K filings that 152 companies we cover made with the SEC in September 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Roivant's subsidiary Dermavant agreed on September 17, 2024 to be acquired by Organon for up to about $1.2 billion, including a $175 million payment at closing, a $75 million milestone on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in sales-based milestones, plus tiered royalties. Roivant owns about 87% of Dermavant's shares, so the deal would deliver most of the proceeds to Roivant, though the amount depends on future milestones and the closing is subject to conditions.
Organon agreed to acquire Dermavant for up to about $1.2 billion in aggregate cash consideration, including a $175 million payment at closing
Additional $75 million payable on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in tiered net sales milestones
Roivant owns approximately 87% of Dermavant's common and preference shares; shareholder written consent of at least 75% of voting rights was obtained
Expected to close in the fourth quarter of 2024; either party may terminate if not closed by March 17, 2025
EPR Properties entered into a Fourth Amended, Restated and Consolidated Credit Agreement on September 19, 2024, providing a new $1.0 billion senior unsecured revolving credit facility with KeyBank as administrative agent. The new facility replaces the prior facility, extends its maturity to October 2, 2028, generally lowers the interest rate on loans, and removes the tangible net worth covenant. For shareholders, the filing describes improved borrowing terms and a $1.0 billion accordion feature, with $169.0 million drawn at September 19, 2024.
Facility size of $1.0 billion, with an accordion feature allowing an increase of $1.0 billion to $2.0 billion subject to lender consent
Maturity extended to October 2, 2028, with two six-month extension options for a total of 12 months
$169.0 million outstanding and $831.0 million available at the close of business on September 19, 2024
Interest rate generally reduced; the tangible net worth covenant was eliminated
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.